ATE540977T1 - Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes - Google Patents

Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes

Info

Publication number
ATE540977T1
ATE540977T1 AT04720380T AT04720380T ATE540977T1 AT E540977 T1 ATE540977 T1 AT E540977T1 AT 04720380 T AT04720380 T AT 04720380T AT 04720380 T AT04720380 T AT 04720380T AT E540977 T1 ATE540977 T1 AT E540977T1
Authority
AT
Austria
Prior art keywords
complex
sclerostin
chordin
tgf
noggin
Prior art date
Application number
AT04720380T
Other languages
English (en)
Inventor
David Winkler
John Latham
John Skonier
Diana Shpektor
Trenton Hayes
James Geoghegan
Original Assignee
Ucb Mfg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Mfg Inc filed Critical Ucb Mfg Inc
Application granted granted Critical
Publication of ATE540977T1 publication Critical patent/ATE540977T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
AT04720380T 2003-03-14 2004-03-12 Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes ATE540977T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45525303P 2003-03-14 2003-03-14
PCT/US2004/007565 WO2004082608A2 (en) 2003-03-14 2004-03-12 Ligands for tgf-beta binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
ATE540977T1 true ATE540977T1 (de) 2012-01-15

Family

ID=33029975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720380T ATE540977T1 (de) 2003-03-14 2004-03-12 Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes

Country Status (15)

Country Link
US (1) US7226902B2 (de)
EP (1) EP1608399B1 (de)
JP (1) JP4660471B2 (de)
AT (1) ATE540977T1 (de)
AU (1) AU2004222317B2 (de)
CA (1) CA2519131C (de)
CY (1) CY1112797T1 (de)
DK (1) DK1608399T3 (de)
ES (1) ES2379689T3 (de)
MX (1) MXPA05009805A (de)
NZ (1) NZ542587A (de)
PL (2) PL378566A1 (de)
PT (1) PT1608399E (de)
SI (1) SI1608399T1 (de)
WO (1) WO2004082608A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007028212A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
EP2069558B1 (de) 2006-10-02 2013-05-01 Sea Lane Biotechnologies,llc. Entwurf und konstruktion für verschiedene synthetische peptide und polypeptid-bibliotheken
EP2460828A3 (de) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antikörper und Diagnose
EP2423226A3 (de) * 2006-11-10 2012-05-30 Amgen Inc. Diagnose und Therapie auf Basis von Antikörpern
EP2114435A1 (de) * 2007-02-02 2009-11-11 Novartis AG Modulatoren für sklerostin-bindende partner zur behandlung von knochenerkrankungen
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
JP6018753B2 (ja) * 2008-11-13 2016-11-02 ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅ Ｇｅｎｅｒａｌ Ｈｏｓｐｉｔａｌ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
EP3712168A3 (de) 2011-12-28 2020-10-14 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3774879B1 (de) 2018-03-30 2026-01-28 Amgen Inc. C-terminale antikörpervarianten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
CA2220912A1 (en) 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
ATE440143T1 (de) 1998-03-30 2009-09-15 Dow Agrosciences Llc Änderung der fettsäure-zusammensetzung in pflanzen durch expression einer aspergillus nidulans delta-9 coa desaturase
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
JP2003525611A (ja) * 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−２分子およびその使用

Also Published As

Publication number Publication date
WO2004082608A2 (en) 2004-09-30
SI1608399T1 (sl) 2012-05-31
US20050085418A1 (en) 2005-04-21
MXPA05009805A (es) 2006-04-18
DK1608399T3 (da) 2012-04-02
PT1608399E (pt) 2012-04-13
WO2004082608A9 (en) 2005-03-17
JP2006522103A (ja) 2006-09-28
EP1608399B1 (de) 2012-01-11
EP1608399A2 (de) 2005-12-28
AU2004222317A1 (en) 2004-09-30
JP4660471B2 (ja) 2011-03-30
ES2379689T3 (es) 2012-04-30
CA2519131A1 (en) 2004-09-30
PL1608399T3 (pl) 2012-09-28
NZ542587A (en) 2008-05-30
CA2519131C (en) 2014-07-08
AU2004222317B2 (en) 2010-08-19
PL378566A1 (pl) 2006-05-02
CY1112797T1 (el) 2016-02-10
WO2004082608A3 (en) 2005-01-20
US7226902B2 (en) 2007-06-05

Similar Documents

Publication Publication Date Title
ATE540977T1 (de) Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes
EA200600037A1 (ru) Композиции и способы увеличения минерализации костей
EA200600038A1 (ru) Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
WO2015138907A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
EP1572937A4 (de) Mit motiven transplantierte hybrid-polypeptide und verwendungen davon
IL191852A (en) Antibodies directed to her-3 and uses thereof
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
EA200870208A1 (ru) Конструкт однодоменного антитела
ATE483472T1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
BRPI0511070A (pt) compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação
ATE538781T1 (de) Neue verwendung von peptidverbindungen zur behandlung von dyskinesie
BRPI0509620A (pt) modulação de nkg2d
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
DE60236921D1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
WO2022031710A3 (en) Multispecific binding agents and uses thereof
ATE498683T1 (de) Leptin antagonisten
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
NO20031033D0 (no) Reseptor i EDb-fibronectindomene
BRPI0507019A (pt) composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su
ATE342274T1 (de) Peptide welche an apo2l (trail) rezeptoren binden und verwendungnen davon
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
ATE552342T1 (de) An der bildung von knöllchen und endomykorrhiza beteiligte ccamk